首页> 外文期刊>Human Pathology >Adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive pulmonary adenocarcinoma-analysis of interobserver agreement, survival, radiographic characteristics, and gross pathology in 296 nodules
【24h】

Adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive pulmonary adenocarcinoma-analysis of interobserver agreement, survival, radiographic characteristics, and gross pathology in 296 nodules

机译:原位腺癌,微浸润性腺癌和浸润性肺腺癌-296个结节的观察者一致性,生存率,影像学特征和总体病理学分析

获取原文
获取原文并翻译 | 示例
           

摘要

The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society and 2015 World Health Organization classifications of lung adenocarcinoma recommend designating tumors showing entirely lepidic growth as adenocarcinoma in situ (AIS) and lepidic tumors with invasion less than or equal to 5 mm as minimally invasive adenocarcinoma (MIA), both of which have superior outcome to conventional invasive adenocarcinoma (IA). Data on interobserver variability within this classification are limited, and further validation of the superior survival of AIS and MIA is needed. A total of 296 surgically excised pulmonary adenocarcinomas were reviewed from 254 patients (1997-2009). Slides were independently reviewed by 2 pulmonary pathologists who categorized tumors as AIS, MIA, or IA. Of 296 nodules, 244 (82.4%) were agreed upon by both observers: 10 AIS, 61 MIA, and 173 IA (kappa = 0.63, good agreement). In 6 cases (2%), there was disagreement between AIS and MIA; in 45 cases (15%), there was disagreement between MIA and IA; and in 1 case, there was disagreement between AIS and IA. Overall survival was significantly different among categories as determined by both observers. Cases with disagreement between MIA and IA had similar survival to agreed MIA. Disease-specific 10-year survival was 100% for AIS (both observers) and 97.3% and 97.6% for MIA, although this did not reach statistical significance compared to IA for either observer. Good agreement was present between observers when classifying tumors as AIS, MIA, and IA. Significant differences in overall survival were present between the 3 groups for both observers, and interobserver variability was evident. Patients with AIS and MIA experienced excellent DSS. (C) 2016 Elsevier Inc. All rights reserved.
机译:国际肺癌研究协会/美国胸腔学会/欧洲呼吸学会和2015年世界卫生组织对肺腺癌的分类建议将完全呈鳞状生长的肿瘤指定为原位腺癌(AIS),将鳞状上皮性肿瘤的侵袭小于或等于微创腺癌(MIA)为5毫米,两者均优于常规浸润性腺癌(IA)。关于该分类内观察者间变异性的数据是有限的,还需要进一步验证AIS和MIA的优异存活率。回顾性分析了254例患者中共296例经手术切除的肺腺癌(1997-2009年)。载玻片由2位肺部病理学家独立审查,他们将肿瘤归类为AIS,MIA或IA。在296个结节中,有244个观察员达成了共识(82.4%):10个AIS,61个MIA和173个IA(kappa = 0.63,良好的一致性)。在6例(2%)中,AIS与MIA之间存在分歧。在45例(15%)中,MIA与IA之间存在分歧;在1例中,AIS与IA之间存在分歧。两位观察员确定,各类别之间的总体生存率显着不同。 MIA和IA之间存在争议的案例的存活率与商定的MIA相似。 AIS(均为观察员)的疾病特异性10年生存率为100%,MIA分别为97.3%和97.6%,尽管与任一观察员的IA相比,这都没有统计学意义。在将肿瘤分类为AIS,MIA和IA时,观察者之间达成了良好的共识。两位观察者在三组之间的总体生存率存在显着差异,并且观察者间的差异也很明显。 AIS和MIA的患者经历了出色的DSS。 (C)2016 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号